SAB Biotherapeutics (SABS)
(Real Time Quote from BATS)
$4.25 USD
0.00 (0.00%)
Updated Apr 29, 2024 03:40 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for SAB Biotherapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -42.19 | -18.74 | -17.14 | -0.01 | NA |
Depreciation/Amortization & Depletion | 3.75 | 3.29 | 1.65 | 0.00 | NA |
Net Change from Assets/Liabilities | 2.33 | -0.24 | 13.45 | 0.00 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 11.00 | -7.77 | 5.79 | 0.00 | NA |
Net Cash From Operating Activities | -25.12 | -23.46 | 3.76 | -0.01 | NA |
Property & Equipment | -0.15 | -2.09 | -10.94 | 0.00 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | -0.15 | -2.09 | -10.94 | 0.00 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 67.16 | 7.76 | 0.01 | 0.03 | NA |
Issuance (Repayment) of Debt | -0.13 | -2.42 | -0.20 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | -0.26 | 1.24 | -0.02 | 0.15 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | 0.00 | -5.52 | 34.34 | -0.08 | NA |
Net Cash from Financing Activities | 66.77 | 1.05 | 34.12 | 0.09 | NA |
Effect of Exchange Rate Changes | 0.02 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | 41.52 | -24.50 | 26.93 | 0.08 | NA |
Cash at Beginning of Period | 15.05 | 39.55 | 12.61 | 0.00 | NA |
Cash at End of Period | 56.57 | 15.05 | 39.55 | 0.08 | NA |
Diluted Net EPS | -7.64 | -4.30 | -6.30 | NA | NA |
Fiscal Year End for SAB Biotherapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -42.19 | -19.34 | -14.23 | -7.35 |
Depreciation/Amortization & Depletion | NA | 3.75 | 2.80 | 1.82 | 0.92 |
Net Change from Assets/Liabilities | NA | 2.33 | 2.75 | 4.25 | 4.21 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 11.00 | 2.11 | 1.67 | 0.61 |
Net Cash From Operating Activities | NA | -25.12 | -11.67 | -6.50 | -1.61 |
Property & Equipment | NA | -0.15 | -0.08 | -0.04 | -0.02 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.15 | -0.08 | -0.04 | -0.02 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 67.16 | 0.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | NA | -0.13 | -0.10 | -0.06 | -0.36 |
Increase (Decrease) Short-Term Debt | NA | -0.26 | -0.77 | -0.66 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 66.77 | -0.86 | -0.72 | -0.36 |
Effect of Exchange Rate Changes | NA | 0.02 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 41.52 | -12.62 | -7.27 | -1.99 |
Cash at Beginning of Period | NA | 15.05 | 15.05 | 15.05 | 15.05 |
Cash at End of Period | NA | 56.57 | 2.43 | 7.77 | 13.06 |
Diluted Net EPS | NA | -3.74 | -1.00 | -1.40 | -1.50 |